Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Debt: 2015-2023

Historic Total Debt for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Total Debt rose 7.79% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $28.3 million for FY2023, which is 7.79% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Total Debt stood at $28.3 million for FY2023, which was up 7.79% from $26.3 million recorded in FY2022.
  • Cartesian Therapeutics' 5-year Total Debt high stood at $28.3 million for FY2023, and its period low was $18.9 million during FY2019.
  • In the last 3 years, Cartesian Therapeutics' Total Debt had a median value of $26.3 million in 2022 and averaged $26.7 million.
  • Its Total Debt has fluctuated over the past 5 years, first declined by 11.60% in 2019, then spiked by 31.15% in 2020.
  • Cartesian Therapeutics' Total Debt (Yearly) stood at $18.9 million in 2019, then skyrocketed by 31.15% to $24.8 million in 2020, then increased by 3.39% to $25.6 million in 2021, then increased by 2.45% to $26.3 million in 2022, then climbed by 7.79% to $28.3 million in 2023.